Kim Hyunjung, Jang Minji, Kim Eunmi
Cancer Molecular Biology Branch, Division of Cancer Biology, National Cancer Center, Goyang-si 10408, Republic of Korea.
Int J Mol Sci. 2025 May 19;26(10):4863. doi: 10.3390/ijms26104863.
Alpha-fetoprotein (AFP) is a well-known biomarker for liver cancer, and its clinical utility is widely recognized. Recent studies have revealed that AFP plays a multifaceted role in various malignant tumors, including liver cancer. This suggests that AFP is not merely a biomarker but also contributes significantly to the complex process of tumor formation, emphasizing the importance of targeting AFP in therapeutic approaches. Consequently, innovative research and development are essential to overcome the current limitations of AFP-targeted therapies, enhance treatment efficacy, and minimize side effects. This review explores the role of AFP in cancer development and progression, highlights the biological functions of AFP and related pathways, and discusses the clinical implications of AFP-targeted therapies. Ongoing research on AFP will significantly contribute to our understanding of the biological mechanisms of cancer and aid in developing effective and safe treatments. Ultimately, advancements in AFP-targeted therapeutic approaches are expected to play a crucial role in the future of cancer management.
甲胎蛋白（AFP）是一种广为人知的肝癌生物标志物，其临床应用已得到广泛认可。最近的研究表明，AFP在包括肝癌在内的各种恶性肿瘤中发挥着多方面的作用。这表明AFP不仅是一种生物标志物，而且在肿瘤形成的复杂过程中也起着重要作用，强调了在治疗方法中靶向AFP的重要性。因此，创新研发对于克服当前AFP靶向治疗的局限性、提高治疗效果和最小化副作用至关重要。本综述探讨了AFP在癌症发生发展中的作用，突出了AFP的生物学功能和相关途径，并讨论了AFP靶向治疗的临床意义。正在进行的关于AFP的研究将极大地有助于我们对癌症生物学机制的理解，并有助于开发有效且安全的治疗方法。最终，AFP靶向治疗方法的进展有望在未来癌症管理中发挥关键作用。
